Attorney Docket No. 54763.8001.US02

I here we certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date:December 13, 2004

Dee Dee Sutherland

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: GJERSET, RUTH ET AL.

APPLICATION No.: 08/335,461

FILED: NOVEMBER 7, 1994

FOR: ENHANCING THE SENSITIVITY OF

TUMOR CELLS TO THERAPIES

EXAMINER: CHRISTOPHER S.F. LOW

1614

CONF. NO: 8495

ART UNIT:

After First Office Action but Before Final Action or Notice of Allowance – 37 C.F.R. § 1.97(c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, whichever occurs first. This information disclosure is being filed in response to the Office communication dated September 8, 2004. The references listed on the enclosed Form PTO-1449 were previously disclosed in the Supplemental Information Disclosure Statement filed March 14, 2003, and are being re-submitted for Examiner's consideration. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application, and the Examiner is requested to make them of record in the application.

2. Cited Information

\boxtimes	Copies of the following references are enclosed:						
		All cited references References marked by asterisks The following:					
	Copie No.	s of the following references can be found in parent U.S. Application :					
		All cited references References marked by asterisks The following:					
	This application was filed after 30 June 2003 and no copies of U.S. patents nor published applications are enclosed (See Notice of Deputy Commissioner Kunin on 11 July 2003).						
	The following references are not in English. For each such reference, the undersigned has enclosed: (i) a translation of the reference; (ii) a copy a communication from a foreign patent office or International Searching Authority citing the reference; (iii) a copy of a reference which appears be an English-language counterpart; or (iv) an English-language abstrated for the reference prepared by a third party. Applicant has not verified the translation, English-language counterpart or third-party abstract is a accurate representation of the teachings of the non-English reference though, and reserves the right to demonstrate otherwise.						
		All cited references References marked by ampersands The following:					


3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

[54763-8001/LA043090.071] 2

∤ .	Fee P	<u>aymer</u>	it (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))						
		Comm	cant believes that no fees are due. However, should the nissioner determine that fees are due in order for this Supplemental nation Disclosure Statement to be considered, the Commissioner is y authorized to charge such fees to Deposit Account No. 50-2586.						
		Applicant submits that no fee is due in light of the following certification under 37 C.F.R. § 1.97(e) (check only one):							
			In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to this filing of this statement; or						
			In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.						
4.	Paten	t Term	Adjustment (37 C.F.R. § 1.704(d))						
		was c applic individ	indersigned states that each item of information submitted herewith ited in a communication from a foreign patent office in a counterpart ration and that this communication was not received by any dual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to ing of this statement. 37 C.F.R. § 1.704(d).						
			Respectfully submitted, Perkins Coie LLP						
Date:_	12/	, /xu							
Jate:_		<u> </u>	Patrick D. Morris Registration No. 53,351						
Corre	spond	ence /	Address:						

Customer No. 34055 Perkins Coie LLP Patent - LA P.O. Box 1208 Seattle, WA 98111-1208 Phone: (310) 788-9900 Fax: (310) 788-3399



				U	.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	U.S. F	Patent or Application Kind Co	ode	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines Where Relevant Passage Relevant Figures Appe	s or	
				FOF	REIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Forei	Foreign Patent or Application Kind Code Office NUMBER (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
	& AA	JP	04009338		Favalli et al.	01/14/92			
	& AB	FR	2688514		Haddada et al.	09/17/93			
	& AC	wo	94/24297		Perricaudet et al.	10/27/94			
	& AD	wo	95/02697		Perricaudet et al.	01/26/95			
	& AE	wo	95/14101		Dedieu et al.	05/26/95			
	& AF	wo	95/23867		Denefle et al.	09/08/95			
	& AG	JP	08508879		Perricaudet et al.	09/24/96			
	7.00								
<u> </u>	T	1			T-NON PATENT LITERATURE		e) title of the item		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.						Т_	
	* AH	KUMAR <i>et al.</i> , "Activation of <i>ras</i> Oncogenes Preceding the Onset of Neoplasia," AH Science, 248:1101-1104, 1990.							
	* AI	MAGRATH et al., "Tumor-Specific Antisense Oligonucleotides for Controlling Cancer," Abstract No. 114:5578n, Chemical Abstracts, 114(7):68, 1991.							
	* AJ	Proceedings of the American Association for Cancer Research, Vol. 36, p. 21, March 1995.							
	* AK				"Radiation and Apoptosis," <i>G</i>	an To Kagak	u Ryoho,		

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and no	
considered. Include copy of this form with next communication to application(s).	

DATE CONSIDERED

EXAMINER